79 results about "Interstitial cell" patented technology

The invention provides an aggregation-induced emission molecule, a nano motor and a preparation method and application of the aggregation-induced emission molecule, the aggregation-induced emission molecule is used for near-infrared emission, has photo-thermal properties, and has the characteristics of near-infrared II region luminescence, heat production and good light stability; the nano motor is prepared by taking an asymmetric double-mesoporous nano material with different pore diameters as a support material and selectively loading aggregation-induced emission molecules on one side of the support material with a larger pore diameter; under the irradiation of near-infrared light, the aggregation-induced emission molecules with the photothermal effect can form a non-uniform thermal gradient to push the self-thermophoresis movement of the nano motor; tumor sites can be diagnosed and reported under the mediation of near-infrared II region imaging; through the photo-thermal effect, the motor can destroy tumor interstitial cells and degrade tumor matrix components; and in combination with autothermophoresis, blood vessels can be penetrated, so that penetration to the deep layer of the tumor can be realized.

The invention belongs to the technical field of biological medicine, and particularly discloses an artificial valve tissue calcification model and a preparation method and application thereof. The preparation method comprises the following steps: providing human valvular interstitial cells; the method comprises the following steps: providing a hydrogel system, wherein the hydrogel system comprises type I collagen, fibrinogen and Matrigel matrigel; constructing an engineered heart valve tissue strip by taking the hydrogel system as a skeleton structure between valve interstitial cells; and culturing the engineered heart valve tissue strip by using a calcification induction culture solution, so that the valve tissue generates a calcification phenotype. The model provided by the invention can generate a valve calcification phenotype which is similar to that after human heart valve calcification and is represented by valve interstitial cell activation, extracellular matrix remodeling such as collagen mass secretion and calcium deposition region generation. The model provided by the invention is low in cost, can be produced in batches, meets the research on the pathogenesis of extracorporeal valve calcification, and makes up for the dilemma that no artificial valve calcification model is available for drug research and development at present.

The invention belongs to the field of biological medicines, and particularly relates to a method for inhibiting osteogenic differentiation of human aortic valve interstitial cells (hVICs), namely, N-acetyltransferase 10 (NAT10) is silenced in vivo and in vitro by a biological method, and the NAT10 is over-silenced in a mouse body by adeno-associated viruses according to the method, so that the result shows that the mouse aortic valve calcification can be inhibited by the silencing of the NAT10, and the osteogenic differentiation of the human aortic valve interstitial cells (hVICs) can be inhibited. NAT10 is silenced in hVICs through adenovirus, and it is found that NAT10 silencing can inhibit osteogenic differentiation of hVICs, so that valve calcification is delayed or inhibited. The invention further provides a method for preventing and treating aortic valve calcification by inhibiting the NAT10 protein expression level, and a new non-surgical treatment scheme is provided for preventing and treating calcified aortic valve diseases.

The invention discloses a human NLRP7 mutation decidua type organ and application thereof, and belongs to the technical field of construction of type organs. The human NLRP7 mutant decidua organ is preserved in the China Center for Type Culture Collection, and is named as the human NLRP7 mutant decidua organ N7LLY (Homo sapiens), the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2024375, and the preservation date is November 06, 2024. The human NLRP7 mutant decidua-like organ is applied to construction of a model for simulating an in-vivo NLRP7 mutant embryo decidua-like organ, and is applied to screening of drugs with prevention or treatment effects on grape embryo or embryo implantation failure. The human NLRP7 mutant decidua-like organ provided by the invention has endometrial epithelial cells and interstitial cells at the same time, expresses receptivity-related markers, and can retain pathological mutation and disease phenotypes of patients in vitro.

The application discloses a kind of hepatic organoids containing mesenchyme induction method, belong to organoid culture technical field.The method includes the following steps: (1) human embryonic stem cell WIBR3 pretreatment;(2) utilize human embryonic stem cell WIBR3 and induce liver organoids and mesenchymal cells;(3) mesenchymal cells and liver organoid cells are co-cultured, i.e. obtain the hepatic organoids containing mesenchyme.There is beneficial effect: the application changes the culture mode and method of the hepatic organoids containing mesenchyme.The hepatic organoids containing mesenchyme induction method proposed in the application is simple, and mesenchymal cells and other liver cells have the same genetic background source, suitable for the safety evaluation of drug and other chemical substances, liver fibrosis, non-alcoholic hepatitis modeling and pharmacodynamic evaluation.

The invention discloses a Nur77 methylation site mutation peptide based on structural modification design and application of the Nur77 methylation site mutation peptide in promoting embryo implantation, according to the mutation peptide, arginine at the 346th site of Nur77 is mutated into lysine, and methylation modification of Nur77 is reserved while phosphorylation of Nur77 is inhibited, so that the transcriptional activity of Nur77 is enhanced. It is found that the mutant peptide can promote deciduation of endometrial interstitial cells, remarkably improve deciduation disorder of infertility mice in in-vivo experiments and improve the embryo planting rate of low-fertility mice. Therefore, the mutant peptide is expected to become a new medicine for treating the uterine-derived infertility and has important clinical application value. The invention also relates to a preparation method of the mutant peptide and application of the mutant peptide in a pharmaceutical composition and a treatment method.

The invention discloses application of Gli1 + interstitial cells or SMOC2 protein thereof in diagnosis, treatment and prognosis evaluation of Crohn disease intestinal stenosis. The invention provides application of Gli1 + interstitial cells and SMOC2 protein as targets in preparation of a diagnostic kit or a therapeutic drug for Crohn disease fibrostenosis, and further provides the diagnostic kit for Crohn disease fibrostenosis and the therapeutic drug for Crohn disease fibrostenosis. Meanwhile, the invention further provides application of the reagent for detecting the expression quantity of the SMOC2 in preparation of the kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis and the corresponding kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis. The invention discusses the effect of the Gli1 + interstitial cells in the attack of intestinal fibrostenosis, evaluates the potential of the Gli1 + interstitial cells as a diagnosis and treatment target, and provides a new thought for the treatment of Crohn disease intestinal stenosis.

The invention discloses a method for enriching and identifying tumor cells with different phenotypes based on double-antibody double-particle-size magnetic beads. Epithelial cell specific cell adhesion molecules and interstitial cell specific waveform proteins are combined with magnetic beads with different particle sizes, so that epithelial, interstitial and mixed specific markers of the same cell in a living cell state can be enriched and identified at one time. The magnetic beads specifically capture target cells with different phenotypes, the captured target cells are separated in a cell sorter under the action of a magnetic field, the phenotypes of the target cells are identified according to different particle sizes of the magnetic beads adhered to the target cells, and on the basis, subsequent analysis of more markers can be further performed. According to the invention, epithelial, mesenchymal and mixed target cells can be simultaneously captured from various body fluids in a living cell state, typing and counting can be rapidly carried out through the particle sizes of the magnetic beads adhered to the surfaces of the cells, the living target cells are analyzed more accurately, and the clinical and scientific research application values are improved.

The invention relates to the technical field of biology, in particular to application of rosa roxburghii tratt active extract in preparation of a medicine for treating dyszoospermia. The extract provided by the invention is prepared from roxburgh rose fruits or roxburgh rose pomace through extraction and enrichment, the raw material resources are rich, the price is low, and the toxic and side effects are low. Animal experiments show that the roxburgh rose active extract has the activity of improving dyszoospermia, and the roxburgh rose active extract can obviously increase the sperm concentration and motility rate of mice with dyszoospermia, reduce the malformation rate and obviously increase the thickness of spermatogenic epithelium, the number of supporting cells and the number of interstitial cells of testicular tissues of the mice with dyszoospermia. WB detection analysis shows that the action way of improving the dyszoospermia by the roxburgh rose active extract is to inhibit activation of an oxidative stress Keap1 / Nrf2 signal channel. The rosa roxburghii tratt active extract has a new function of improving dyszoospermia and can be applied as a medicine for improving dyszoospermia.

The invention relates to the technical field of biological medicine, and discloses rapamycin-loaded microemulsion gel as well as a preparation method and application thereof. The preparation method of the microemulsion gel comprises the following steps: dissolving N, N-dimethyl octadecyl carboxymethyl chitosan in a water phase, then adding an oil phase, a cosurfactant and rapamycin, and stirring to obtain rapamycin-loaded microemulsion; the preparation method comprises the following steps: dissolving a high polymer material in a PBS solution, heating until the high polymer material is completely dissolved, then adding dopamine, stirring for reaction, and finally dialyzing and freeze-drying to obtain the adhesive. And adding a gel matrix containing a thickening agent and an adhesive into the microemulsion, and stirring to obtain the rapamycin-loaded microemulsion gel. According to the prepared microemulsion gel, transdermal drug delivery of hydrophobic drugs is achieved, testis are coated with the microemulsion gel loaded with rapamycin, the blocking effect of damp-heat stress on differentiation and development of testis interstitial cells can be relieved, and the functionality of a male reproduction endocrine system is recovered.

The application provides a WNT5B-promoting tooth differentiation biological product and an application thereof. Compared with the prior art, the application has the following advantages: the patent integrates human embryonic tooth germ spatial transcriptome sequencing and epithelial cell and interstitial cell extracellular protein group sequencing data, screens signal molecules WNT5B and CTNNB1 secreted in the development process of tooth germ epithelium, and confirms the important role of WNT5B protein in tooth germ development for the first time. Compared with other WNT family members, WNT5B has stronger tooth-forming ability of promoting tooth-derived stem cells; the effective concentration of WNT5B is low, and 10 ng / ml is the optimal concentration of WNT5B for promoting tooth-derived stem cells to form teeth; and the role of WNT5B and CTNNB1 in extracellular secretion of tooth germ epithelial cells and the synergistic effect of WNT5B and CTNNB1 in promoting tooth differentiation of tooth germ mesenchymal cells are further determined, that is, the combined low-concentration use effect of the two is better than the single high-concentration use.

The utility model relates to a kind of human adenomyosis ectopic epithelium and stromal cell separation culture devices. The device includes L-shaped base, fixed tube, centrifugal tube, filter separation component. Two centrifugal tubes are used to collect stromal cell and epithelial cell respectively, and the top end of centrifugal tube is connected with top cover. Filter separation component includes mounting ring, locating ring, flexible filter screen, annular frame and positioning mechanism. Mounting ring is horizontally arranged, locating ring is peripherally arranged on mounting ring, and locating ring is adapted to the top end of centrifugal tube, filter screen is arranged at the bottom of mounting ring, the bottom of annular frame is connected with the bottom surface of flexible filter screen, gap is provided between the top of annular frame and mounting ring, and annular frame is limited by positioning mechanism. Compared with prior art, the utility model can simplify the separation process of human adenomyosis ectopic epithelium and stromal cell, reduce cleaning work, and is suitable for laboratory culture operation.

The invention belongs to the technical field of biological medicine research, and particularly relates to a cell in-vitro calcification inducer, an induction culture medium and application thereof, an aortic valve calcification in-vitro induction model and a modeling method thereof. The inducer provided by the invention is prepared from the following components in parts by weight: 2160.4 parts of beta-sodium glycerophosphate, 0.039 parts of dexamethasone, 50 parts of vitamin C and 34 parts of vitamin D. The invention further provides a culture medium formed by using the inducer and a method for modeling an aortic valve calcification in-vitro induction model by using the inducer. According to the method, osteogenic differentiation of the aortic valve interstitial cells can be stably induced within a short time, an efficient and repeatable standardized induction scheme is provided for in-vitro aortic valve calcification models and drug screening, and the method has a very good application prospect.

The invention provides a WNT5B dental differentiation promoting biological product and application thereof. Compared with the prior art, the application has the following advantages: by integrating human embryo tooth embryo space transcriptome sequencing data and epithelial cell and interstitial cell exocrine proteome sequencing data, signal molecules WNT5B and CTNNB1 secreted in the tooth embryo epithelial development process are screened out, the important effect of the WNT5B protein in tooth embryo development is confirmed for the first time, and the application has a wide application prospect. Compared with other WNT family members, the WNT5B has higher capability of promoting the tooth formation of the odontogenic stem cells; the onset concentration of the WNT5B is low, and the onset concentration is the optimal concentration of the WNT5B for promoting the odontogenic stem cells to form teeth when the onset concentration is 10ng / ml; the effects of the WNT5B and the CTNNB1 in tooth embryo epithelial cell exocrine and the synergistic effect of the WNT5B and the CTNNB1 in promoting tooth embryo mesenchymal cell odontogenic differentiation are further determined, namely the combined low-concentration use effect of the WNT5B and the CTNNB1 is superior to that of single high-concentration use of the WNT5B and the CTNNB1.

The invention belongs to the field of biological medicine, and relates to application of triptolide in preparation of a medicine for preventing and treating calcified aortic valve diseases. The triptolide is found to be capable of promoting expression and maturation of CTSD and activating enzyme activity of the CTSD, meanwhile, biogenesis of lysosome in valvular interstitial cells can be promoted by regulating and controlling AKT / mTOR / TFEB signal axes, lysosome functions are improved, autophagy flux is recovered, and finally the effect of treating the calcified aortic valve disease is achieved. A novel treatment medicine is provided for the calcified aortic valve disease.

The invention relates to medical application of an asparagine endopeptidase inhibitor in mitral valve mucus-like degeneration, and belongs to the technical field of biological medicine. The invention provides an application of an asparagine endopeptidase inhibitor in preparation of a medicine for treating mitral valve mucus-like degeneration. The invention relates to an application in preparation of a medicine for relieving mitral valve insufficiency. The invention relates to application in preparation of a medicine for inhibiting mitral valve thickening. The invention also discloses an application of the LGMN in preparing a medicine for treating mitral valve mucus-like degeneration by inhibiting the LGMN secreted by the in-situ macrophages. According to the application disclosed by the invention, the LGMN secreted by the macrophages is subjected to targeted antagonism, so that the myofibroblast transformation of the valvular interstitial cells is delayed, and a new target spot and a treatment path are provided for precise treatment of the mitral valve mucus-like degeneration.

The invention provides a method for auxiliary identification of PD-L1 expression of a colorectal cancer patient by using a patient ascites-derived tumor-like cell cluster (PTC), and a kit for identifying the PD-L1 expression of the colorectal cancer patient by using the PD-L1 expression of the colorectal cancer patient. PTC is a result of self-assembly and proliferation of tumor cells, primary epithelial cells, interstitial cells, fibroblasts and immune cells, an ascites sample can be utilized to be cultured into tumor microspheres within a short time, and the obtained tumor microspheres have high consistency with original tumors. PD-L1 detection can be provided for patients who cannot obtain tissue slices by utilizing the PTC derived from malignant effusion of colorectal cancer patients, and the feasibility of receiving immunotherapy is provided for the patients.

This invention belongs to the field of biomedical technology and relates to the application of OSM inhibitors in the preparation of drugs for the prevention or treatment of calcific aortic valve disease. This invention reveals for the first time that OSM drives osteogenic differentiation and calcified nodule formation of valvular interstitial cells through the OSM-OSMR-JAK2 / JAK3-STAT3-RUNX2 signaling axis, which is the core pathogenic mechanism leading to calcific aortic valve disease. This invention utilizes anti-OSM neutralizing antibodies or sulforaphane to effectively block this signaling axis, significantly inhibiting macrophage infiltration, valvular calcification, and improving hemodynamic abnormalities. This invention provides a precise target and a novel strategy for the modification therapy of calcific aortic valve disease, solving the technical problem of the ineffectiveness of traditional broad-spectrum anti-inflammatory therapy in valvular calcification.

The invention relates to the technical field of genetic engineering, in particular to application of PCK1 in preparation of products for regulating and controlling goat testicular interstitial cell proliferation. According to the invention, an over-expression plasmid pcDNA3.1 (+)-PCK1 of the PCK1 gene is constructed, an interference sequence si-PCK1 of the PCK1 gene is synthesized, and it is proposed for the first time that the over-expression of the PCK1 gene can significantly promote the proliferation of goat testicular interstitial cells, and the inhibition of the expression of the PCK1 gene can significantly inhibit the proliferation of the goat testicular interstitial cells. The invention has important significance for improving the development of the goat testis, and provides technical support for researching and developing related products for regulating and controlling the proliferation of the goat testis interstitial cells by taking the PCK1 gene as the target spot.

The invention provides application of disulfiram in preparation of a medicine for treating calcified aortic valve diseases, and belongs to the field of biological medicine. The disulfiram is used for intervening in-vitro cultured valvular interstitial cells and a mouse in-vivo calcified aortic valve stenosis model, and experimental results show that the disulfiram can inhibit the capability of differentiating the valvular interstitial cells to osteogenic phenotypes, relieve extracellular calcification deposition and relieve aortic valve calcification and stenosis. Therefore, the disulfiram can be used as a medicine for treating the calcified aortic valve disease and has a wide application prospect.

The invention discloses application of H-151 in preparation of drugs for preventing and treating calcified aortic valve diseases, relates to the technical field of biological medicines, and is characterized in that the invention provides application of an STING inhibitor H-151 or pharmaceutically acceptable salts thereof in preparation of drugs for preventing and / or treating calcified aortic valve diseases. The invention reveals for the first time that H-151 can inhibit the increase of the expression level of osteogenic differentiation markers ALP and RUNX2 in aortic valve interstitial cells induced by an osteogenic culture medium in an in-vitro experiment, and inhibit osteogenic differentiation and calcium salt deposition of the aortic valve interstitial cells; in addition, aortic valve thickening, fibrosis and calcium salt deposition of mice induced by an aortic valve injury model are inhibited in vivo. Based on the biological effect, the application of H-151 in developing the medicine for treating the calcified aortic valve disease is provided for the first time, and a new technical path and a new medicine choice are provided for preventing and treating the calcified aortic valve disease.

The invention discloses an establishment method and application of an iPSCs (induced pluripotent stem cells)-derived valvular interstitial cell calcification model, and belongs to the technical field of cell model establishment. The construction method of the iPSCs-derived valvular interstitial cell calcification model comprises the following steps: (1) carrying out induced differentiation for 7 days by using the combination of four regulatory factors, namely BMP4, CHIR99021, VEGF and Forskolin, so as to differentiate mature valvular interstitial cells; and (2) culturing the iPSCs-derived valvular interstitial cells in the step (1) in an osteogenic induction culture medium at 37 DEG C under the condition of 5% CO2 for at least 3 days. The invention provides a rapid and efficient differentiation scheme, the mature valvular interstitial cells induced by the scheme are very close to human primary valvular interstitial cells, and a high-quality experimental platform is provided for screening and mechanism research of anti-calcification drugs.

The application discloses a device for predicting the recurrence / metastasis risk of a non-small cell lung cancer patient after operation and application thereof, adopts multiple machine learning algorithms to combine the clinical characteristics, genomic sequencing data and immune microenvironment infiltration characteristics of real world non-small cell lung cancer patients with disease-free survival, and constructs a postoperative recurrence prediction model. Through a Lasso coefficient path diagram, it is confirmed that five characteristics including tumor size, tumor interstitium CD8+ T cell positive rate, tumor parenchyma M2 type tumor-related macrophage positive rate, TP53 gene mutation state and postoperative ctDNA-MRD state are included in model construction, and a MIMIR prediction model is constructed through a random survival forest. The model can help clinicians to accurately evaluate the postoperative disease-free survival of non-small cell lung cancer patients, guide the development of individualized treatment and follow-up schemes, and bring better survival benefits to patients.

The invention discloses a primary culture method of mesenteric interstitial cells, which relates to the technical field of cell culture, and is characterized by comprising the following steps: selecting mice with a growth cycle of more than 4 weeks, separating mesenteric tissues of the mice, treating the mesenteric tissues by using mesothelial cell dissociation liquid to remove mesothelial cells; the method comprises the following steps: separating mesenteric interstitial cells by using a physical cutting and enzyme digestion method, purifying the cells by using a Ficoll / Percoll density gradient centrifugation method, finally carrying out multiplication culture on the mesenteric interstitial cells in a culture medium containing itaconic acid derivatives, and carrying out passage operation when the cell confluence degree reaches 80%. The cell culture method provided by the invention effectively avoids mixing of mesothelial cells, endothelial cells and other cells, can promote the mesenteric interstitial cells to adhere to the wall and grow as soon as possible, improves the cell amplification rate, and reduces the cell culture cycle.

The invention relates to the technical field of cosmetics, and aims to provide a preparation method of a peony-containing double-resistant composition, which utilizes a compound enzyme technology to decompose components such as cellulose, hemicelluloses and pectin in cell walls and intercellular substances of moutan barks and destroy cell wall structures through the synergistic effect of cellulase, hemicelluloses and pectinase so as to improve the anti-inflammatory effect of the peony barks. And paeonol in cells can be released more easily, so that the extraction efficiency is improved, and the extraction time is shortened.

The invention relates to the technical field of genetic engineering, in particular to application of miR-145-3p as a target spot in preparation of products for regulating and controlling proliferation of goat testicular interstitial cells. According to the invention, Inhibitor and Mimics sequences taking the miR-145-3p gene as a target spot are constructed, and it is proposed for the first time that overexpression of the miR-145-3p gene can significantly inhibit proliferation of goat testicular interstitial cells, and inhibition of the miR-145-3p gene can significantly promote proliferation of goat testicular interstitial cells. The invention has important significance for improving the development of the goat testis, and provides technical support for researching and developing related products for regulating and controlling the proliferation of the goat testis interstitial cells by taking the miR-145-3p gene as a target spot.

The invention aims to provide a method for separating and amplifying placenta decidua matrix cells in a perinatal period. The method comprises the following steps: adding decidua tissues into a culture medium A containing collagenase for digestion treatment; cleaning to obtain a cell suspension A, and sieving to obtain a cell suspension B; mixing the cell suspension B with a Ficoll solution, and carrying out primary gradient centrifugation; mixing the cell layer and the supernate layer with normal saline, and then carrying out secondary gradient centrifugation; and culturing the cell block mass and the culture medium B in an incubator. According to the method, the success rate of separation and amplification of the placenta decidua interstitial cells in the perinatal period can be increased, the separated and proliferated cells have group cell biomarker expression for tissue repair, and the separation technical method is improved, so that highly purified cells are obtained.

The invention belongs to the technical field of reproductive biology, and particularly provides a method for separating and culturing testicular perichondrial muscle-like cells of an adult mouse. The method comprises the following steps: removing interstitial cells from testis tissues of an adult mouse, and digesting the testis tissues by pancreatin and DNA enzyme to obtain a testis single-cell suspension; and culturing by adopting a new isolated culture medium until the culture dish is full of cells, and carrying out cell passage, cell cryopreservation and resuscitation and cell identification by adopting passage culture mediums with different concentrations. According to the method for separating and culturing the mouse peridermoid cells, the cell separation degree is far higher than that in the prior art, operation is easy, time is saved, the technical blank that the mouse peridermoid cells are difficult to separate and culture is filled, and the method is suitable for large-scale popularization and application. And convenience is provided for research on interaction of the mouse testicular peritubular muscle-like cells with other testicular somatic cells and germ cells.

This invention provides the application of costunolide in the preparation of a drug for preventing posterior capsule opacification. Costunolide effectively reduces posterior capsule opacification after extracapsular lens extraction (ECLE) and exhibits significant anti-inflammatory and anti-fibrotic effects in both in vitro and in vivo models. Mechanistic studies have identified matrix metalloproteinase 8 (MMP8) as a key downstream effector of costunolide, confirming that costunolide inhibits MMP8 expression, thereby blocking the transformation of lens epithelial cells (LECs) into mesenchymal cells and subsequent fibrotic processes. This lays a solid foundation for developing targeted therapies for posterior cataract, a common surgical complication.

The application discloses a method for synchronously marking germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus, which comprises the following steps: cloning MIR17HG-a (long non-coding RNA) of Paralichthys olivaceus by using a probe primer, obtaining a target plasmid after plasmid extraction, carrying out double enzyme digestion and purification to obtain an enzyme-digested plasmid as a probe template, synthesizing Paralichthys olivaceus MIR17HG-a probe by using an SP6 / T7 RNA polymerase, preparing a tissue slice from the testis tissue of Paralichthys olivaceus, and carrying out fluorescent in situ hybridization on the tissue slice by using the Paralichthys olivaceus MIR17HG-a probe, so that the Paralichthys olivaceus MIR17HG-a probe can synchronously mark the germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus. The method solves the defects of traditional marking technology, such as the need for combined marking or multiple step-by-step marking, and fills the blank of synchronous marking of germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus.